ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1366

Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients

Nevin Hammam1,2, Shaimaa Salah3, Anthony Marotta4 and Emad F. Kholef5, 1Rheumatology and Rehabilitation Department, University of Assiut, Assiut, Egypt, 2University of Alberta, Edmonton, AB, Canada, 3Rheumatology, Rehabilitation and Physical Medicine department, Faculty of Medicine, Assiut, Assiut, Egypt, 4Augurex Life Sciences Corp., Vancouver, BC, Canada, 5Clinical Pathology Department, Aswan University Hospital, Aswan, Egypt

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: joint damage, radiography, rheumatoid arthritis (RA) and synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in severe joint

damage and physical disability, therefore, the discovery of new marker(s) for joint

destruction is needed. Serum 14-3-3η protein is a novel diagnostic marker for RA, and

also involved in joint damage (1, 2). 14-3-3η protein has been reported to be expressed at

significantly higher levels in synovial fluid (SF) of RA patients when compared with

matched serum by immunoblot analysis (1). Correlation of serum 14-3-3η protein with

clinical variables, autoantibodies, inflammatory markers, and radiologic damage has

been examined in RA (2). These associations have never been examined for RA

synovial fluid (SF) 14-3-3η protein. In this study, we quantified SF 14-3-3η by ELISA

and determined the association of serum and SF14-3-3η protein with clinical, laboratory

and radiographic damage in RA.

Methods:

RA patients diagnosed according to 2010 ACR criteria were included. Serum and SF

samples were obtained from all patients at the same day and 14-3-3η protein levels

were measured using the quantitative 14-3-3η ELISA kit (Augurex Life Sciences Corp).

A 14-3-3η cut-off of ≥ 0.19 ng/ml, the diagnostic cut-off was employed. Radiological

damage was evaluated using Sharp/van der Heijde score (SHS). Spearman or Pearson

correlations to compare relationships and Mann-Whitney U test for groups difference

were used for statistical analysis.

Results:

A total of 39 RA patients, mean age of 38 years, with 87.2% being female were

included. Their mean disease duration was 9.3 years, and 48.7% of patients had

moderate DAS28. Mean SF14-3-3η protein levels were 2 fold higher than mean serum

protein levels (3.7 vs 1.7 ng/ ml). The prevalence of 14-3-3η protein positivity was

higher in SF compared with serum from RA patients; 82.1% versus 69.2%, respectively.

Although there was significant correlation between SF 14-3-3η protein levels and ESR

(p=0.036), no significant association was found between serum or SF 14-3-3η protein

levels with DAS28 or autoantibodies in RA. There was significant correlation between

serum and SF 14-3-3η protein levels (p<0.05) in RA patients. Serum and SF 14-3-3η

protein levels were positively correlated with SHS (p<0.001). RA patients who were

serum or SF 14-3-3η protein positive showed significant difference in SHS but not in

clinical and laboratory features when compared with 14-3-3η negative patients.

Conclusion:

14-3-3η levels are significantly higher in SF than in matched serum. Serum and SF14-3-

3η protein levels correlate with radiographic damage. This study further substantiates

14-3-3η as a mechanistic joint damage marker for RA.

References:

1. Kilani et al. J Rheumatology 2007, 34 (8).

2. Maksymowych et al. Arthritis Research Therapy 2014,16: R99.


Disclosure: N. Hammam, None; S. Salah, None; A. Marotta, Augurex Life Sciences, 3; E. F. Kholef, None.

To cite this abstract in AMA style:

Hammam N, Salah S, Marotta A, F. Kholef E. Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-synovial-fluid-14-3-3%ce%b7-protein-as-a-marker-of-joint-damage-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-synovial-fluid-14-3-3%ce%b7-protein-as-a-marker-of-joint-damage-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology